Preladenant

DB11864InvestigationalSmall molecule

Preladenant has been used in trials studying the treatment of Brain Diseases, Parkinson Disease, Movement Disorders, Antipsychotic Agents, and Parkinsonian Disorders, among others.

Mechanism: Pharmacologically active on Adenosine receptor A2a
Curator reviewed
Formula / weight: C₂₅H₂₉N₉O₃ · 503.567 g/mol (avg)
Code names: MK-3814 · SCH 420814

Resolves to

Compound

UNII950O97NUPOCAS377727-87-2ChEMBLCHEMBL240624PubChem10117987

Structure

InChIKeyDTYWJKSSUANMHD-UHFFFAOYSA-NSMILESCOCCOC1=CC=C(C=C1)N1CCN(CCN2N=CC3=C2N=C(N)N2N=C(N=C32)C2=CC=CO2)CC1

Targets

P29274ADORA2A

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Preladenant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account